ClinicalTrials.gg
CompletedNCT00784550ADC111114Updated Nov 23, 2016Results posted

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

A Phase 4 interventional study of Tiotropium Bromide and Fluticasone Propionate/Salmeterol in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 35 sites in United States. Open to participants aged 40 Years to 99 Years. Per ClinicalTrials.gov, last updated 2016-11-23.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
342
Allocation
Randomized
Ages
40 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 4 under way, 1 of them phase 3. Fluticasone · Pulmonary Disease, Chronic Obstructive.

Enrollment
20th of 59
342 · median 95
Started
2008
with 1 other
Phase 4
28 of 59
2 open now
Registered
13th of 59
by date
Lead sponsor
25 of 59
GlaxoSmithKline

Among the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, this one is the 20th largest by enrollment, is one of 2 that started in 2008, is one of 28 in phase 4, and was the 13th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of the study is to determine the efficacy and safety of the combination of ADVAIR DISKUS® 250/50mcg (FLUTICASONE PROPIONATE/SALMETEROL COMBINATION PRODUCT) plus SPIRIVA® HANDIHALER® inhaler 18mcg (TIOTROPIUM) compared to SPIRIVA® HANDIHALER® inhaler 18mcg (TIOTROPIUM) in patients with COPD.

SPIRIVA® and HANDIHALER® are trade marks of Boehringer Ingelheim Pharma GmbH \& Co. KG.

ADVAIR DISKUS® are registered trademarks of the GSK group of companies.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • Spirometry
  • COPD
04

Who can participate

Ages eligible
40 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis
  • At least 10 pack year smoking history
  • Post-albuterol greater than or equal to 40% to less than or equal to 80% of predicted normal
  • An FEV1/FVC ratio of less than or equal to 0.70

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of asthma
  • Other respiratory disorder other than
  • Abnormal and clinical significant
  • Chest x-ray abnormality not believed to be due to COPD
  • of greater than or equal to 40/kg/m2
  • Use of Long Term Oxygen Therapy
  • Lung resection surgery
  • Women pregnant or lactating at Visit 1
  • Previously diagnosed cancer unless in complete remission for 2 years at Visit 1
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
342 participants (actual)

Study arms

  • Experimental
    ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler

    Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Plus Tiotropium Bromide 18 mcg QD

    Drug: Fluticasone Propionate/Salmeterol

  • Active comparator
    SPIRIVA® HANDIHALER® inhaler

    Tiotropium Bromide 18mcg QD plus Placebo DISKUS BID

    Drug: Tiotropium Bromide

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-dose Forced Expiratory Volume in One Second (FEV1) at Endpoint

    Change from baseline was calculated as the Endpoint (defined as the last recorded measure of AM pre-dose FEV1 for each participant) value minus the baseline value. FEV1 is defined as the amount of air expelled from the lungs in one second after a full inspiration and is a measure of pulmonary function.

    Time frame: Baseline and Endpoint (defined as the last recorded measure [taken up to Week 24] of AM pre-dose FEV1 for each participant)

Secondary outcomes

  1. Mean Change From Baseline in 2 Hour Post-dose FEV1 at Endpoint

    Change from baseline was calculated as the Endpoint (defined as the last recorded measure of 2 hour post-dose FEV1 for each participant) value minus the baseline value. FEV1 is defined as the amount of air expelled from the lungs in one second after a full inspiration and is a measure of pulmonary function.

    Time frame: Baseline and Endpoint (defined as the last recorded measure [taken up to Week 24] of 2 hour post-dose FEV1 for each participant)

  2. Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-dose Forced Vital Capacity (FVC) at Endpoint

    Change from baseline was calculated as the Endpoint (defined as the last recorded measure of AM pre-dose FVC fore each participant) value minus the baseline value. FVC is defined as the amount of air that can forcibly be blown out after a full inspiration.

    Time frame: Baseline and Endpoint (defined as the last recorded measure [up to Week 24] of AM pre-dose FVC for each participant)

  3. Mean Change From Baseline in 2 Hour Post-dose FVC at Endpoint

    Change from baseline was calculated as the Endpoint (defined as the last recorded measure of 2 hour post-dose FVC for each participant) value minus the baseline value. FVC is defined as the amount of air that can forcibly be blown out after a full inspiration (FVC).

    Time frame: Baseline and Endpoint (defined as the last recorded measure of 2 hour post-dose FVC [up to Week 24] for each participant)

  4. Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-Dose Inspiratory Capacity (IC) at Endpoint

    Change from baseline was calculated as the Endpoint (defined as the last recorded measure of AM pre-dose IC for each participant) value minus the baseline value. IC is defined as the amount of air that can be inhaled after a normal expiration. IC is a measure of pulmonary function.

    Time frame: Baseline and Endpoint (defined as the last recorded measure of AM pre-dose IC [up to Week 24] for each participant)

  5. Mean Change From Baseline in Scores on the Chronic Respiratory Disease Questionnaire-Self-Administered Standardized (CRQ-SAS) at Endpoint

    The CRQ-SAS measures 4 domains of functioning of participants with COPD: mastery (amount of control the participant feels he/she has over COPD symptoms); fatigue (how tired the participant feels); emotional function (how anxious/depressed the participant feels); and dyspnea (how short of breath the participant feels during physical activities). Each domain is measured on a scale of 1-7 (1=maximum impairment; 7=no impairment). Each domain score is calculated separately.

    Time frame: Baseline and Endpoint (defined as the last recorded score [up to Week 24 or the early withdrawal visit] on each of the questions on this questionnaire)

07

Results

Posted Dec 10, 2010

Participant flow

Participant flow — Overall Study
MilestoneFSC + TioTiotropium
Started173169
Completed137127
Not completed3642
Withdrew: Adverse event1210
Withdrew: Lack of efficacy01
Withdrew: Protocol violation1010
Withdrew: Lost to follow-up85
Withdrew: Physician decision23
Withdrew: Withdrawal by subject413

Outcome measures

PrimaryMean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-dose Forced Expiratory Volume in One Second (FEV1) at Endpoint

Change from baseline was calculated as the Endpoint (defined as the last recorded measure of AM pre-dose FEV1 for each participant) value minus the baseline value. FEV1 is defined as the amount of air expelled from the lungs in one second after a full inspiration and is a measure of pulmonary function.

Time frame:
Baseline and Endpoint (defined as the last recorded measure [taken up to Week 24] of AM pre-dose FEV1 for each participant)
Reported as:
Mean · milliliters (ml)
Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-dose Forced Expiratory Volume in One Second (FEV1) at Endpoint
milliliters (ml)FSC + TioTiotropium
Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-dose Forced Expiratory Volume in One Second (FEV1) at Endpoint101 ± 21.8-16 ± 20.4
Statistical analysis
  • FSC + Tio vs Tiotropium · ANCOVA · p = <0.001
SecondaryMean Change From Baseline in 2 Hour Post-dose FEV1 at Endpoint

Change from baseline was calculated as the Endpoint (defined as the last recorded measure of 2 hour post-dose FEV1 for each participant) value minus the baseline value. FEV1 is defined as the amount of air expelled from the lungs in one second after a full inspiration and is a measure of pulmonary function.

Time frame:
Baseline and Endpoint (defined as the last recorded measure [taken up to Week 24] of 2 hour post-dose FEV1 for each participant)
Reported as:
Mean · ml
Mean Change From Baseline in 2 Hour Post-dose FEV1 at Endpoint
mlFSC + TioTiotropium
Mean Change From Baseline in 2 Hour Post-dose FEV1 at Endpoint233 ± 23.177 ± 20.6
Statistical analysis
  • FSC + Tio vs Tiotropium · ANCOVA · p = <0.001
SecondaryMean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-dose Forced Vital Capacity (FVC) at Endpoint

Change from baseline was calculated as the Endpoint (defined as the last recorded measure of AM pre-dose FVC fore each participant) value minus the baseline value. FVC is defined as the amount of air that can forcibly be blown out after a full inspiration.

Time frame:
Baseline and Endpoint (defined as the last recorded measure [up to Week 24] of AM pre-dose FVC for each participant)
Reported as:
Mean · ml
Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-dose Forced Vital Capacity (FVC) at Endpoint
mlFSC + TioTiotropium
Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-dose Forced Vital Capacity (FVC) at Endpoint95 ± 32.7-28 ± 30.6
Statistical analysis
  • FSC + Tio vs Tiotropium · ANCOVA · p = 0.006
SecondaryMean Change From Baseline in 2 Hour Post-dose FVC at Endpoint

Change from baseline was calculated as the Endpoint (defined as the last recorded measure of 2 hour post-dose FVC for each participant) value minus the baseline value. FVC is defined as the amount of air that can forcibly be blown out after a full inspiration (FVC).

Time frame:
Baseline and Endpoint (defined as the last recorded measure of 2 hour post-dose FVC [up to Week 24] for each participant)
Reported as:
Mean · ml
Mean Change From Baseline in 2 Hour Post-dose FVC at Endpoint
mlFSC + TioTiotropium
Mean Change From Baseline in 2 Hour Post-dose FVC at Endpoint265 ± 35.987 ± 31.2
Statistical analysis
  • FSC + Tio vs Tiotropium · ANCOVA · p = <0.001
SecondaryMean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-Dose Inspiratory Capacity (IC) at Endpoint

Change from baseline was calculated as the Endpoint (defined as the last recorded measure of AM pre-dose IC for each participant) value minus the baseline value. IC is defined as the amount of air that can be inhaled after a normal expiration. IC is a measure of pulmonary function.

Time frame:
Baseline and Endpoint (defined as the last recorded measure of AM pre-dose IC [up to Week 24] for each participant)
Reported as:
Mean · ml
Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-Dose Inspiratory Capacity (IC) at Endpoint
mlFSC + TioTiotropium
Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-Dose Inspiratory Capacity (IC) at Endpoint107 ± 28.4-8 ± 28.1
Statistical analysis
  • FSC + Tio vs Tiotropium · ANCOVA · p = <0.001
SecondaryMean Change From Baseline in Scores on the Chronic Respiratory Disease Questionnaire-Self-Administered Standardized (CRQ-SAS) at Endpoint

The CRQ-SAS measures 4 domains of functioning of participants with COPD: mastery (amount of control the participant feels he/she has over COPD symptoms); fatigue (how tired the participant feels); emotional function (how anxious/depressed the participant feels); and dyspnea (how short of breath the participant feels during physical activities). Each domain is measured on a scale of 1-7 (1=maximum impairment; 7=no impairment). Each domain score is calculated separately.

Time frame:
Baseline and Endpoint (defined as the last recorded score [up to Week 24 or the early withdrawal visit] on each of the questions on this questionnaire)
Reported as:
Mean · points on a scale
Mean Change From Baseline in Scores on the Chronic Respiratory Disease Questionnaire-Self-Administered Standardized (CRQ-SAS) at Endpoint
points on a scaleFSC + TioTiotropium
Mastery0.28 ± 0.0780.04 ± 0.090
Fatigue0.23 ± 0.0940.17 ± 0.091
Emotional Function0.24 ± 0.0720.16 ± 0.073
Dyspnea0.21 ± 0.0910.19 ± 0.091
Statistical analysis
  • FSC + Tio vs Tiotropium · ANCOVA · p = 0.069 (Mastery domain)
  • FSC + Tio vs Tiotropium · ANCOVA · p = 0.470 (Fatigue domain)
  • FSC + Tio vs Tiotropium · ANCOVA · p = 0.394 (Emotional function domain)
  • FSC + Tio vs Tiotropium · ANCOVA · p = 0.879Dyspnea domain

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FSC + Tio—7/173 (4%)34/173 (19.7%)
Tiotropium—13/169 (7.7%)29/169 (17.2%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventFSC + TioTiotropium
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/1735/169
IleusGastrointestinal disorders0/1731/169
Lower gastrointestinal hemorrhageGastrointestinal disorders0/1731/169
EsophagitisGastrointestinal disorders0/1731/169
Gastric infectionInfections and infestations0/1731/169
Gastroenteritis viralInfections and infestations0/1731/169
Bone neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1731/169
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1731/169
Non-cardiac chest painGeneral disorders1/1731/169
Splenic ruptureInjury, poisoning and procedural complications0/1731/169
Most frequent other events
Most frequent other events
EventFSC + TioTiotropium
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders24/17324/169
HeadacheNervous system disorders11/1739/169

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FSC + TioTiotropiumTotal
Mean61.3 ± 8.5661.0 ± 9.4161.2 ± 8.98
Sex: Female, Male
Sex: Female, Male(Participants)FSC + TioTiotropiumTotal
Female8696182
Male8773160
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)FSC + TioTiotropiumTotal
White165162327
African American/African Heritage7714
American Indian or Alaska Native101
08

Study locations

35 sites
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    Fort Collins, Colorado 80528, United States
  • GSK Investigational Site
    Clearwater, Florida 33756, United States
  • GSK Investigational Site
    Deland, Florida 32720, United States
  • GSK Investigational Site
    Naranja, Florida 33032, United States
  • GSK Investigational Site
    Coeur D'Alene, Idaho 83814, United States
  • GSK Investigational Site
    Gillespie, Illinois 62033, United States
  • GSK Investigational Site
    Elkhart, Indiana 46514, United States
  • GSK Investigational Site
    Olathe, Kansas 66061, United States
  • GSK Investigational Site
    Louisville, Kentucky 40207, United States
  • GSK Investigational Site
    Shreveport, Louisiana 71103, United States
  • GSK Investigational Site
    Sunset, Louisiana 70584, United States
  • GSK Investigational Site
    St. Charles, Missouri 63301, United States
  • GSK Investigational Site
    Omaha, Nebraska 68131, United States
  • GSK Investigational Site
    Albany, New York 12205, United States
  • GSK Investigational Site
    Elizabeth City, North Carolina 27909, United States
  • GSK Investigational Site
    Mooresville, North Carolina 28117, United States
  • GSK Investigational Site
    Statesville, North Carolina 28625, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Cleveland, Ohio 44122, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16508, United States
  • GSK Investigational Site
    Cumberland, Rhode Island 02864, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406-7108, United States
  • GSK Investigational Site
    Gaffney, South Carolina 29340, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Union, South Carolina 29379, United States
  • GSK Investigational Site
    Milan, Tennessee 38358, United States
  • GSK Investigational Site
    Boerne, Texas 78006, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Houston, Texas 77054, United States
  • GSK Investigational Site
    Plano, Texas 75024, United States
  • GSK Investigational Site
    West Jordan, Utah 84088, United States
  • GSK Investigational Site
    Newport News, Virginia 23606, United States
  • GSK Investigational Site
    Richmond, Virginia 23229, United States
09

References and documents

Publications

  • Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012 Jan;106(1):91-101. doi: 10.1016/j.rmed.2011.09.002. Epub 2011 Oct 29. PubMed 22040533 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 1 year after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2008
First posted
Nov 4, 2008
Start
Dec 2008
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results delay requested
Aug 12, 2010
Results first posted
Dec 10, 2010
Last update
Nov 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00784550
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 4, 2008
Start date
Dec 2008
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Dec 10, 2010
Last update
Nov 23, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate

Start the discussion